Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.88% | -0.33% | -2.46% | -3.92% | -5.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.88% | -0.33% | -2.46% | -3.92% | -5.16% |
| Cost of Revenue | 3.54% | 1.81% | -3.12% | -4.69% | -6.85% |
| Gross Profit | -4.57% | -2.14% | -1.88% | -3.25% | -3.69% |
| SG&A Expenses | -0.76% | -1.52% | -4.05% | -3.75% | -3.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.24% | 3.12% | -0.78% | -1.84% | -3.71% |
| Operating Income | -16.19% | -23.01% | -14.15% | -18.28% | -14.46% |
| Income Before Tax | 16.17% | 126.02% | -519.66% | -175.56% | -436.93% |
| Income Tax Expenses | 26.41% | 132.39% | -382.53% | -134.17% | -711.49% |
| Earnings from Continuing Operations | 13.20% | 124.08% | -571.33% | -189.38% | -388.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.20% | 124.08% | -571.33% | -189.38% | -388.81% |
| EBIT | -16.19% | -23.01% | -14.15% | -18.28% | -14.46% |
| EBITDA | -8.25% | -14.20% | -8.66% | -11.59% | -9.31% |
| EPS Basic | 10.92% | 125.03% | -637.13% | -202.81% | -376.51% |
| Normalized Basic EPS | -12.44% | -20.79% | -11.21% | -18.96% | -13.86% |
| EPS Diluted | 11.09% | 124.94% | -634.96% | -202.54% | -367.41% |
| Normalized Diluted EPS | -12.40% | -20.72% | -11.12% | -18.78% | -13.63% |
| Average Basic Shares Outstanding | -3.14% | -3.22% | -3.01% | -3.41% | -3.47% |
| Average Diluted Shares Outstanding | -3.19% | -3.31% | -3.10% | -3.61% | -3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |